Outcomes with the MitraClip® device in the ACCESS-EUrope Phase I trial

The MitraClip Therapy Economic and Clinical Outcomes Study Europe (ACCESS-EU) enroled 117 patients with degenerative mitral regurgitation (MR) considered ineligible for surgery. Mortalities at 30 days and 12 months were 6.0 and 17.1%, respectively. At 12 months, 74.6% (53 of 71) of patients in follow-up achieved significant reductions in MR and improved clinical outcomes. This complementary non-surgical intervention should be indicated by an inter-disciplinary team of cardiologists and cardiac surgeons.